PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director
Board appointment will help guide target identification and drug discovery
Cambridge, UK, 15 July 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director. Dr Mayr’s experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will help drive the expansion of PhoreMost’s next-generation SITESEEKER® target discovery platform and guide the development of the Company’s drug discovery programme.
Dr Mayr is Chief Technology Officer at GE Healthcare Life Sciences, where he is responsible for R&D strategy and innovation across all life sciences business areas. He has extensive global experience in pharmaceutical R&D, including holding positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis Pharmaceuticals and Bayer Pharmaceuticals. Dr Mayr gained his PhD at the University of Bayreuth in Biochemistry and Biophysics, subsequently completing his PostDoc at the M.I.T/Whitehead Institute in Cambridge, US.
Dr Chris Torrance Chief Executive Officer, PhoreMost, said: “Lorenz’s expertise and global industry leadership will be invaluable in shaping PhoreMost’s future development as a fully integrated target identification and drug discovery company. As a key thought leader in functional screening and novel modalities we are particularly proud to welcome him to our Board.”
Dr Lorenz Mayr, Non-Executive Director, PhoreMost, commented: “The convergence of biology and technology is an innovative and industry-changing area which opens the door to identify many new drug targets and improved therapies, not previously seen with conventional methods. Such is the potential of the SITESEEKER platform and I am extremely pleased to join the PhoreMost Board at a pivotal stage in the Company’s development. I look forward to working with the team to support its progress and bring novel therapies to market.”
The SITESEEKER platform is based on PhoreMost’s core proprietary protein interference or ‘PROTEINi’ technology. Using SITESEEKER, PhoreMost is able to probe the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the massive 3-D shape diversity of natural protein fragment (sub-domain) libraries. This enables the systematic unmasking of cryptic druggable sites, directly linking them to useful therapeutic functions.
PhoreMost Ltd media enquiries
Phone: +44 (0)7787 502 947
At PhoreMost Ltd
Dr Chris Torrance, CEO
About PhoreMost Ltd www.phoremost.com
PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.